Skip to main content
    E

    Elevance Health Inc (ELV)

    Official site

    HEALTHCARE • HEALTHCARE PLANS • NYSE

    $446.42
    +16.73 (+3.89%)

    Market Cap: $92.84B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Elevance Health Inc (ELV) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Elevance Health (ELV) to earn $29.14 per share in the fiscal year ending Dec 31, 2026, on revenue of $198.85B. Of 22 analysts, 15 rate the stock Buy or Strong Buy, 7 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 20 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 22 ratings average 2.18, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 68% of the ratings.

    RatingAnalystsShare
    Strong Buy313.6%
    Buy1254.5%
    Hold731.8%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    22

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 3.9% and revenue estimates rise 2.5%.

    Fiscal year ending Dec 31, 2026
    $29.14
    EPS consensus, revenue $198.85B
    Fiscal year ending Dec 31, 2027
    $30.29
    EPS consensus, revenue $203.75B
    Next report
    Jan 26, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$29.14$28.65 to $30.2821$198.85B$196.78B to $200.05B12
    Dec 31, 2027$30.29$29.95 to $31.7521$203.75B$197.12B to $209.77B12

    Quarterly Estimates

    The EPS consensus rises from $2.08 for the quarter ending Dec 31, 2026 to $12.32 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.08$1.61 to $3.3823$49.74B$46.08B to $52.81B19
    Mar 31, 2027$12.32$8.69 to $13.2314$50.06B$49.26B to $51.06B7

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 47 upward and 5 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 2026200
    Fiscal year ending Dec 31, 2027191
    Quarter ending Mar 31, 202784

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 7.3% from $27.16.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$29.14$29.14$27.20$27.16$27.16+7.3%
    Fiscal year ending Dec 31, 2027$30.29$30.29$29.58$29.61$29.63+2.2%
    Quarter ending Mar 31, 2027$12.32$12.14$12.12$12.03$12.03+2.4%

    Frequently Asked Questions About ELV

    What is the ELV stock forecast?

    Consensus analyst estimates put Elevance Health's EPS at $29.14 for the fiscal year ending Dec 31, 2026, on revenue of $198.85B. The consensus rating from 22 analysts is Buy.

    How do analysts rate ELV stock?

    Of 22 analysts covering Elevance Health, 3 rate it Strong Buy, 12 Buy, 7 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from ELV next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $29.14, with estimates from $28.65 to $30.28 from 21 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $30.29, with estimates from $29.95 to $31.75 from 21 analysts.

    What revenue do analysts expect from Elevance Health next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $198.85B, with estimates from $196.78B to $200.05B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $203.75B, with estimates from $197.12B to $209.77B.

    How many analysts cover ELV?

    22 analysts rate Elevance Health stock, and 21 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.